IVD资讯综合复星公告据药圈观察局报道，复星医药旗下药友制药已收到辉瑞支付的首付款15000万美元（约合10.5亿元）。复星医药12月10日公告，控股子公司药友制药就口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂（包括 YP05002）及含有该活性成分的产品授予辉瑞于许可区域（即全球范围）及领域（即人类、动物所有适应症的治疗、诊断及预防）独家开发、使用、生产及商业化权利；就本次许可，药友...
Source LinkIVD资讯综合复星公告据药圈观察局报道，复星医药旗下药友制药已收到辉瑞支付的首付款15000万美元（约合10.5亿元）。复星医药12月10日公告，控股子公司药友制药就口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂（包括 YP05002）及含有该活性成分的产品授予辉瑞于许可区域（即全球范围）及领域（即人类、动物所有适应症的治疗、诊断及预防）独家开发、使用、生产及商业化权利；就本次许可，药友...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.